MIRM Mirum Pharmaceuticals Inc

Mirum Pharmaceuticals is set to raise $68.5 million through a private placement of common stock and pre-funded warrants with TCGX. This financing is expected to close around January 2, 2025, and will involve the sale of approximately 4.8 million shares and 5.7 million pre-funded warrants at a price of $6.50 per share/pre-funded warrant.

Rice Hall James & Associates LLC significantly reduced its stake in Mirum Pharmaceuticals (NASDAQ:MIRM) by 29.0%, selling 67,247 shares and ending the third quarter with 164,746 shares valued at $12.08 million. Despite this, Mirum Pharmaceuticals exceeded Q3 earnings estimates with $0.05 EPS and $133 million in revenue, leading analysts to maintain a "Buy" rating and an average price target of $100.25, with some raising their targets. The company, focused on therapies for rare cholestatic liver diseases, reported strong revenue growth but still faces negative net margins.

Mirum Pharmaceuticals announced it will raise $68.5 million through a private placement of common stock and pre-funded warrants with TCGX. The funding is expected to extend Mirum's cash runway into the second half of 2026. The offering is anticipated to close around March 18, 2024.

Mirum Pharmaceuticals director Michael G. Grey sold 50,000 shares of common stock for $3.9 million after exercising options, holding no direct shares but retaining significant indirect and option holdings. This transaction came as MIRM shares traded near their 52-week high and were considered overbought according to InvestingPro. The company has also been active in patent infringement lawsuits and secured new funding, leading to increased price targets from analysts.

Saira Ramasastry, a director at Mirum Pharmaceuticals, sold 5,000 shares of common stock for $400,000. This transaction occurred on December 22, 2025, near the company's 52-week high, and was executed under a Rule 10b5-1 trading plan. Despite the sale, Ramasastry also exercised options to purchase 5,000 shares on the same day.

Mirum Pharmaceuticals (MIRM) has achieved an IBD SmartSelect Composite Rating of 96, improving from 94 the previous day, indicating it outperforms 96% of all stocks based on key fundamental and technical criteria. This places MIRM in an elite group, as winning stocks often have a Composite Rating of 95 or higher. The biotech company has recently seen its RS Rating rise to 92 and has reached an all-time high, with related news highlighting its strong performance and a 236% rocket in liver drug stock amid FDA approval and accelerated sales.